Pinnacle Summer Investments’s Galectin Therapeutics GALT Stock Holding History

Pinnacle Summer Investments’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$0	Hold	167	–	–	﹤0.01%	864
2015 Q3	$0	Hold	167	–	–	﹤0.01%	1010
2015 Q2	$0	Hold	167	–	–	﹤0.01%	820
2015 Q1	$1K	Hold	167	–	–	﹤0.01%	967
2014 Q4	$1K	Hold	167	–	–	﹤0.01%	982
2014 Q3	$1K	Hold	167	–	–	﹤0.01%	1022
2014 Q2	$3K	Hold	167	–	–	﹤0.01%	892
2014 Q1	$2K	Hold	167	–	–	﹤0.01%	886
2013 Q4	$1K	Hold	167	–	–	﹤0.01%	921
2013 Q3	$2K	Hold	167	–	–	﹤0.01%	849
2013 Q2	$1K	Buy	+167	New	+$684	﹤0.01%	796

Other funds holding GALT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

BCCM

Blue Clay Capital Management Minneapolis, Minnesota $88.7M AUM 6.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Pinnacle Summer Investments's GALT Position: Q4 2015 in Review

Pinnacle Summer Investments held its Galectin Therapeutics (GALT) position steady in Q4 2015 at 167 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #864.

Pinnacle Summer Investments first reported a position in GALT in Q2 2013 and has held it in 11 quarters since. The position peaked at $3K in Q2 2014. 58 funds tracked by Wall St. Rank hold GALT as of Q4 2015.

Pinnacle Summer Investments held 167 shares of Galectin Therapeutics worth $0 as of Q4 2015.
Pinnacle Summer Investments left its Galectin Therapeutics share count unchanged in Q4 2015.
Galectin Therapeutics made up ﹤0.01% of Pinnacle Summer Investments's portfolio in Q4 2015, its #864 holding.
Pinnacle Summer Investments first reported a position in Galectin Therapeutics in Q2 2013 and has held it in 11 quarters since.
Pinnacle Summer Investments's Galectin Therapeutics position peaked at $3K in Q2 2014.
58 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2015.

Based on Pinnacle Summer Investments's 13F filing for Q4 2015, filed 16 Feb 2016.